UTHR Q3 2020 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

UTHRUnited Therapeutics Corporation

$24B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$380M-5.3% YoY

Gross Profit

$356M93.7% margin

Operating Income

$221M58.2% margin

Net Income

$171M45.0% margin

EPS (Diluted)

$3.84

QoQ Revenue Growth

+5.0%

Cash Flow

Operating Cash Flow

$251M

Free Cash Flow

$235M

Stock-Based Comp.

-$13M

Balance Sheet

Total Assets

$4.4B

Total Liabilities

$1.1B

Stockholders' Equity

$3.3B

Cash & Equivalents

$670M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$380M	$402M	-5.3%
Gross Profit	$356M	$369M	-3.4%
Operating Income	$221M	$183M	+20.6%
Net Income	$171M	$132M	+29.3%

Revenue Segments

Tyvaso

$130M34%

Remodulin

$125M33%

Orenitram

$75M20%

Unituxin

$38M10%

Adcirca

$14M4%

Geographic Segments

UNITED STATES

$369M97%

European Union And Others

$11M3%